Cetera Advisor Networks LLC Has $62.62 Million Stake in Johnson & Johnson (NYSE:JNJ)

Cetera Advisor Networks LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.7% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 378,322 shares of the company’s stock after acquiring an additional 10,095 shares during the period. Cetera Advisor Networks LLC’s holdings in Johnson & Johnson were worth $62,620,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Independent Advisor Alliance raised its position in Johnson & Johnson by 0.9% during the second quarter. Independent Advisor Alliance now owns 153,337 shares of the company’s stock worth $25,380,000 after acquiring an additional 1,327 shares in the last quarter. Peak Asset Management LLC raised its position in Johnson & Johnson by 9.3% during the first quarter. Peak Asset Management LLC now owns 13,789 shares of the company’s stock worth $2,137,000 after acquiring an additional 1,171 shares in the last quarter. Nisa Investment Advisors LLC raised its position in Johnson & Johnson by 0.9% during the first quarter. Nisa Investment Advisors LLC now owns 748,842 shares of the company’s stock worth $116,071,000 after acquiring an additional 6,836 shares in the last quarter. Vaughan Nelson Investment Management L.P. raised its position in Johnson & Johnson by 21.8% during the first quarter. Vaughan Nelson Investment Management L.P. now owns 903,546 shares of the company’s stock worth $140,050,000 after acquiring an additional 161,687 shares in the last quarter. Finally, Tekla Capital Management LLC raised its position in shares of Johnson & Johnson by 12.8% in the first quarter. Tekla Capital Management LLC now owns 721,779 shares of the company’s stock valued at $111,876,000 after purchasing an additional 82,100 shares during the period. Institutional investors and hedge funds own 68.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on JNJ shares. Barclays increased their price objective on shares of Johnson & Johnson from $158.00 to $162.00 and gave the company an “equal weight” rating in a research report on Thursday, October 12th. Morgan Stanley lowered their price target on shares of Johnson & Johnson from $174.00 to $171.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 18th. TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday. Royal Bank of Canada initiated coverage on shares of Johnson & Johnson in a research note on Wednesday, October 4th. They set an “outperform” rating and a $178.00 price objective on the stock. Finally, Wells Fargo & Company reduced their price objective on shares of Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a research note on Thursday, August 31st. Eight equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $169.19.

Johnson & Johnson Stock Up 0.9 %

Johnson & Johnson stock opened at $149.91 on Tuesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $181.04. The firm has a 50 day moving average price of $154.52 and a two-hundred day moving average price of $160.29. The firm has a market cap of $360.88 billion, a price-to-earnings ratio of 11.13, a PEG ratio of 3.00 and a beta of 0.58.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 17th. The company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.52 by $0.14. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. The firm had revenue of $21.35 billion during the quarter, compared to analyst estimates of $21 billion. Equities analysts predict that Johnson & Johnson will post 10.1 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 5th. Shareholders of record on Tuesday, November 21st will be issued a dividend of $1.19 per share. The ex-dividend date is Monday, November 20th. This represents a $4.76 annualized dividend and a yield of 3.18%. Johnson & Johnson’s payout ratio is 35.34%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.